Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis.
| Autor: | Han, D., Wang, G., Sun, L., Ren, X., Shang, W., Xu, L., Li, S. |
|---|---|
| Předmět: |
ANTINEOPLASTIC agents
CHI-squared test COMPARATIVE studies CONFIDENCE intervals DRUG toxicity ETOPOSIDE HEALTH INFORMATION storage & retrieval systems MEDICAL databases LUNG cancer MEDLINE META-analysis PROBABILITY theory SYSTEMATIC reviews BIBLIOGRAPHIC databases RELATIVE medical risk DATA analysis software IRINOTECAN INFERENTIAL statistics ODDS ratio THERAPEUTICS |
| Zdroj: | European Journal of Cancer Care; Nov2017, Vol. 26 Issue 6, pn/a-N.PAG, 8p, 1 Diagram, 1 Chart, 7 Graphs |
| Abstrakt: | This meta-analysis was performed to compare the effects and toxicities between irinotecan/platinum ( IP) and etoposide/platinum ( EP) regimens as the fist-line treatment of patients with extensive-stage small cell lung cancer (E- SCLC). A systematic search was made of MEDLINE, Cochrane, ISI Web of Science and SCOPUS databases. Randomised clinical trials on treatment of E- SCLC with the IP regimens, compared with EP regimens, were reviewed. Studies were pooled to hazard ratio ( HR), relative risk ( RR) and odds ratio ( OR), with 95% confidence interval ( CI). Eight trials (enrolling 2089 participants) met the inclusion criteria. Overall survival ( OS) and 1-year survival rate were superior in the IP group ( HR 0.83; 95% CI 0.75 to 0.91 and RR 1.19; 95% CI 1.06 to 1.34). Grades 3 and 4 anaemia, leukopenia, neutropenia, thrombocytopenia and febrile neutropenia were less frequent in the IP regimens than that in the EP regimens. And grades 3 and 4 nausea/vomiting, diarrheal, anorexia and fatigue were less frequent in the EP regimens. IP combination chemotherapy achieved a superior OS and 1-year survival rate, compared with EP doublets, in patients with E- SCLC. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|